A first-of-its-kind hepatitis B drug, bepirovirsen, showed potential for a functional cure in international studies, with about one-fifth of treated patients maintaining undetectable virus levels for six months after stopping all therapy.

Early data suggest lower baseline S protein levels may be linked to higher response rates, as researchers investigate why only some patients respond.

Trials funded by GSK and Ionis compared weekly bepirovirsen injections plus standard therapy against a placebo, and the control group did not achieve a functional cure.

Regulatory submissions are underway with agencies in the US, Canada, Europe, Japan, and China, with decisions anticipated later this year that could open a new therapeutic pathway if approved.

Chronic hepatitis B carries a high burden and, if bepirovirsen proves durable and safe, could signal a major shift in disease management and outcomes.

The potential public health impact is significant given the global burden of hepatitis B and the limitations of existing therapies.

Current tools—safe vaccination, diagnostics, and antivirals—remain essential, but access is uneven, highlighting global health inequities.

Despite potential benefits, accessibility and affordability concerns loom in low-resource regions, along with possible side effects affecting platelets, kidney function, and injection sites.

Experts view the results as promising but not universally applicable, noting reduced benefit for patients with cirrhosis or HIV, and questions about generalizability to all groups.

Note: Full article is behind a paywall and accessible to subscribers in this edition.

The ultimate goal is to diagnose, link patients to care, and prevent progression to liver disease or cancer, with bepirovirsen potentially becoming a cornerstone of future cure strategies.

GSK holds the operational license for bepirovirsen through a collaboration with Ionis, enabling development and potential commercialization.